gastroparesis symptoms glp-1 GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment Your guide to GLP-1 side

What is Micro-Dosing of GLP-1 Agonists

Norovirus GII.17 has rapidly overtaken GII.4 as the leading cause of norovirus outbreaks in the United States between 2022 and 2025

See which health clubs already do, plus the integration models, vendors, and compliance in the quarterly Inspire360 report.

Bad breath can develop during GLP-1 therapy, but it's usually manageable with simple oral hygiene adjustments

To address this growing global challenge, the World Health Organization (WHO) has developed a guideline on the use of glucagon-like peptide-1 (GLP-1) based therapies, including GLP-1 receptor agonists and GLP-1/GIP dual agonists, for adults living with obesity.Join us at the virtual launch event in a webinar hosted by WHO in collaboration with the Journal of the American Medical Association (JAMA) on 1 December 2025 at 16:00 CET

Novo Nordisk, Eli Lilly, Pfizer, Amgen and Roche are the major companies operating in this market.